Intermune CEO asks Supreme Court to review off-label marketing conviction

08/12/2013 | PharmaLive.com

Former Intermune CEO W. Scott Harkonen is asking the Supreme Court to review his conviction for wire fraud in a case involving off-label marketing of Actimmune. Harkonen issued a press release stating that a clinical trial confirmed Actimmune's efficacy against idiopathic pulmonary fibrosis, though the drug was not FDA-approved for that indication. Harkonen asserts that the conviction violates his right to free speech and that the statements he made were not false or misleading.

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory FDA
Cardinal Health
Columbus, OH
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA